South Korea based Standigm, a company using artificial intelligence (AI) technology for drug discovery and development, has announced that Younsung Choo has been appointed Chief Executive Officer (CEO). As the new CEO of Standigm, Choo will focus primarily on company strategy, planning, R&D and business development. 

Choo has served as an advisor to Standigm since 2018. In his new role, Choo will help guide the company and its employees through a challenging economic climate, with a focus on promising drug discovery and repurposing innovations and diverse drug discovery projects. Standigm spent several years developing its platform based on in-house and external collaboration projects and is ready to showcase its capabilities under Choo's leadership.

Choo brings to Standigm vast experience from his past work. Notably, he was the project leader for Korea's first US Food and Drug Administration (FDA) new drug, Factive, approval. He worked for LG Life Sciences for more than twenty years in various roles, including Head of R&D, Director of Global Business, and Director of Pharmaceutical Business.